Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: A retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index

Bone Marrow Transplantation

Volumn 21, Issue 3, 1998, Pages 263-271

  Fanin, R ^a   Silvestri, F ^a   Geromin, A ^a   Infanti, L ^a   Sperotto, A ^a   Cerno, M ^a   Stocchi, R ^a   Savignano, C ^a   Rinaldi, C ^a   Damiani, D ^a   Baccarani, M ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Autologous transplantation; International Prognostic Index; Non Hodgkin's lymphoma

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 17144446875     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701081     Document Type: Article

References (49)

1. Philip T, Biron P, Maraninchi D et al. Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non-Hodgkin's lymphoma. Br J Haematol 1985; 60: 599-609.
2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
3. Shipp MA, Harrington DP, Klatt MM et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-765.
4. Velasquez WS, Jagannath S, Tucker SL et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74: 551-557.
5. Jones SE, Miller TP, Connors JM. Long term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989; 9: 1186-1191.
6. Hoskins PJ, Ng V, Spinelli JJ et al. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991; 9: 220-226.
7. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Aggresifs. J Clin Oncol 1991; 9: 211-219.
8. Hayward RL, Leonard RCF, Prescott RI, with the members of the Scotland and Newcastle Lymphoma Group Therapy Working Party. A critical analysis of prognostic factors for survival in intermediate and high grade NHL. Br J Cancer 1991; 63: 945-952.
9. Coleman CN, Picozzi VJ, Cox RS et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1628-1637.
10. Mazza P, Bertini M, Macchi S et al. Lymphoblastic lymphoma in adolescents and adults. Clinical, pathological and prognostic evaluation. Eur J Cancer Clin Oncol 1986; 22: 1503-1510.
11. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has 'high-risk' disease? Blood 1994; 83: 1165-1173.
12. Stansfeld AG, Diebold J, Kapanci Y et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292-293.
13. Falini B, Pileri S, Martelli MF. Histological and immunohistological analysis of human lymphomas. Crit Rev Oncol/Hematol 1989; 9: 351-419.
14. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
15. Bastion Y, Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 1994; 12: 1340-1342.
16. Lopez-Guillermo A, Montserrat E, Bosch F et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-1348.
17. Hermans J, Krol ADG, van Groningen K et al. International prognostic index for aggressive non-Hodgkin's lymphomas is valid for all malignancies grades. Blood 1995; 86: 1460-1463.
18. Fielding AK, Goldstone AH. Autografting in intermediate-and high-grade non-Hodgkin's lymphoma. Forum 1995; 5: 617-625.
19. Vose JM, Bierman PJ, Anderson J et al. Patients with diffuse aggressive non-Hodgkin's lymphoma (NHL) transplanted within one year of initial diagnosis: improved outcome with transplantation planned as part of initial therapy. Blood 1995; 86 (Suppl. 1): 458a (Abstr. 1820).
20. Pettengell R, Radford JA, Morenstern GR et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586-592.
21. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
22. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1362-1392.
23. Zaja F, Russo D, Silvestri F et al. Computed tomography, magnetic resonance and 67-Gallium scintigraphy for the imaging of residual lymphoma. Haematologica 1995; 80: 574-578.
24. Mandelli F, Annino L, Vegna ML et al. GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results. Leukemia 1992; 6 (Suppl. 2): 182-185.
25. Infanti L, Silvestri F, Fanin R et al. The F-MACHOP regimen in the treatment of high risk non-Hodgkin's lymphomas: a single centre experience in 72 patients. Haematologica 1996; 81: 521-528.
26. Guglielmi C, Amadori S, Anselmo AP et al. Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine and prednisone (F-MACHOP). Cancer Invest 1987; 5: 159-169.
27. Guglielmi C, Amadori S, Martelli M et al. The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results. Ann Oncol 1991; 2: 365-371.
28. Damiani D, Fanin R, Silvestri F et al. Randomized trial of autologous Filgrastim-primed bone marrow transplantation versus Filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997; 90: 36-42.
29. Fanin R, Silvestri F, Geromin A et al. Primary systemic CD30 (Ki-1 )-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (± radiotherapy) and autologous bone marrow transplantation. Blood 1996; 87: 1243-1248.
30. Martelli M, Vignetti M, Zinzani PL et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534-542.
31. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994; 12: 2543-2551.
32. Verdonck LF, van Putten WLJ, Hagenbeer A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. New Engl J Med 1995; 332: 1045-1051.
33. Fanin R, Silvestri F, Geromin A et al. Sequential intensive treatment with the F-MACHOP regimen (± radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult. Leuk Lymphoma 1997; 24: 369-377.
34. Chabner BA, Bates SE, Fojo AT et al. Drug resistance in adult lymphomas. Semin Hematol 1994; 31: 70-87.
35. Fielding AK, Philip T, Carella AM et al. Autologous bone marrow transplantation for lymphomas: a 15-year European Bone Marrow Transplant Registry experience of 3325 patients. Blood 1994; 84 (Suppl. 1): 536a (Abstr. 2130).
36. Sweetenham JW, Liberti G, Pearce R et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994; 12: 1358-1365.
37. Milpied N, Ifrah N, Kuentz M et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989; 73: 82-87.
38. Santini G, Coser P, Chisesi T et al. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG). Ann Oncol 1991; 2 (Suppl. 2): 181-185.
39. Baro J, Richard C, Sierra J et al. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma response to conventional dose chemotherapy. Bone Marrow Transplant 1992; 10: 33-38.
40. Verdonck LF, Dekker AW, de Gast GC et al. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992; 10: 644-646.
41. Haq R, Sawka CA, Franssen E et al. Significance of partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol 1994; 12: 1074-1084.
42. Philip T, Hartmann O, Biron P et al. High dose therapy and autologous bone marrow transplantation in partial response after first line induction therapy for diffuse NHL. J Clin Oncol 1988; 6: 1118-1124.
43. Gulati SC, Shank B, Black P et al. Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 1988; 6: 1303-1313.
44. Gribben JG, Goldstone AH, Linch DC et al. Effectiveness of high dose combination chemotherapy and ABMT for patients with NHL who are still responsive to conventional dose chemotherapy. J Clin Oncol 1989: 7: 1621-1629.
45. Colombat P, Gorin NC, Lemonnier MP et al. The role of autologous bone marrow transplantation in 46 patients with NHL. J Clin Oncol 1990; 8: 630-637.
46. Haioun C, Lepage E., Gisselbrecht Ch et al. Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non Hodgkin's lymphoma (NHL) in first complete remission (CR): a study of 541 patients (LNH87-2 protocol). Ann Oncol 1996; 7 (Suppl. 3): 24.
47. Bolwell B, Goormastic M, Zgrabik J et al. Durability of remission after ABMT for NHL: the importance of the two year evaluation point. Blood 1995; 86 (Suppl. 1): 458a (Abstr. 1818).
48. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl J Med 1997; 336: 1290-1297.
49. van Besien K, Tabocoff J, Rodriguez M et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995; 15: 549-555.